[S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination].

Abstract

Peritoneal dissemination (PD) is the most common type of metastasis in advanced gastric cancer. The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy). Here, we describe the results of SP therapy for gastric cancer with PD. Sixteen gastric cancer patients with PD were treated with SP therapy as first-line chemotherapy. Second-look staging laparoscopy was performed for 10 patients who showed a good response to SP therapy. Gastrectomy was performed for 5 patients with P0CY0 and 1 case with P0CY1. The median survival time of all 16 patients was 571 days (19 months). The patients, who had surgery, had a significantly better survival time than the others (25 months vs 12.7 months). In conclusion, SP therapy is effective for gastric cancer with PD, and surgery for cases showing a good response to chemotherapy might improve the prognosis of patients with PD.

• Authors: Takeo Hara, Yoshiyuki Fujiwara, Keijiro Sugimura, Takeshi Omori, Masaaki Motoori, Norikatsu Miyoshi, Hirofumi Akita, Kunihito Gotoh, Hidenori Takahashi, Shogo Kobayashi, Shingo Noura, Masayuki Ohue, Masato Sakon, Masahiko Yano
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 12 Pg. 1466-8 (Nov 2015) ISSN: 0385-0684 [Print] Japan
• PMID: 26805065 (Publication Type: English Abstract, Journal Article)

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Cisplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Drug Combinations
• Female
• Gastrectomy
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Oxonic Acid (administration & dosage)
• Peritoneal Neoplasms (drug therapy, secondary, surgery)
• Prognosis
• Stomach Neoplasms (drug therapy, pathology, surgery)
• Tegafur (administration & dosage)